Advanced search
Publication Cover
Leukemia & Lymphoma Volume 55, 2014 - Issue 12
Submit an article Journal homepage
316
Views
1
CrossRef citations to date
0
Altmetric
Letter

A 5-day outpatient regimen of azacitidine is effective and well tolerated in patients with acute myeloid leukemia unsuitable for intensive chemotherapy

Maeve A. O'ReillyDepartment of Haematology, Beaumont Hospital, Dublin, IrelandCorrespondence[email protected]
,
Cathy McHaleDepartment of Haematology, Adelaide and Meath Hospital Incorporating the National Children's Hospital, Dublin, Ireland
,
Ahmed AlmazmiDepartment of Haematology, Beaumont Hospital, Dublin, Ireland
,
Abdul HameedDepartment of Haematology, Mater Misericordiae Hospital, Dublin, Ireland
,
Dalia BenjaminDepartment of Haematology, Mater Misericordiae Hospital, Dublin, Ireland
,
Niamh O'ConnellDepartment of Haematology, Adelaide and Meath Hospital Incorporating the National Children's Hospital, Dublin, Ireland
,
Philip MurphyDepartment of Haematology, Beaumont Hospital, Dublin, Ireland
,
John QuinnDepartment of Haematology, Beaumont Hospital, Dublin, Ireland
,
Patrick ThorntonDepartment of Haematology, Beaumont Hospital, Dublin, Ireland
,
Peter O'GormanDepartment of Haematology, Mater Misericordiae Hospital, Dublin, Ireland
,
Hana FrankovaDepartment of Haematology, Letterkenny General Hospital, Letterkenny, Ireland
,
Jeremy SargentDepartment of Haematology, Beaumont Hospital, Dublin, Ireland
,
Estelle VerburghDepartment of Haematology, Mater Misericordiae Hospital, Dublin, Ireland
,
John McHughDepartment of Haematology, Adelaide and Meath Hospital Incorporating the National Children's Hospital, Dublin, Ireland
,
Pamela EvansDepartment of Haematology, Adelaide and Meath Hospital Incorporating the National Children's Hospital, Dublin, Ireland
&
Helen EnrightDepartment of Haematology, Adelaide and Meath Hospital Incorporating the National Children's Hospital, Dublin, Ireland
 show all
Pages 2950-2951 | Received 09 Feb 2014, Accepted 26 Feb 2014, Published online: 22 Apr 2014

References

  • Passweg JR, Pabst T, Blum S, et al. Azacitidine for acute myeloid leukemia in elderly or frail patients. Leuk Lymphoma 2014;55:87–91.
  • Rowe JM. Closer to the truth in AML. Blood 2009;113:4129–4130.
  • Kaminskas E, Farrell A, Abraham S, et al. Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes. Clin Cancer Res 2005;11:3604–3608.
  • Al-Ali HK, Jaekel N, Junghanss C, et al. Azacitidine in patients with acute myeloid leukemia medically unfit for or resistant to chemotherapy: a multicenter phase I/II study. Leuk Lymphoma 2012;51:110–117.
  • Sudan N, Rosseti JM, Shadduck RK, et al. Treatment of acute myelogenous leukemia with outpatient azacitidine. Cancer 2006;107: 1839–1843.
  • Maurillo L, Venditti A, Spagnoli A, et al. Azacitidine for the treatment of patients with acute myeloid leukemia: report of 82 patients enrolled in an Italian Compassionate Program. Cancer 2012;118:1014–1022.
  • Quintas-Cardama A, Ravandi F, Liu-Dumlao T, et al. Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia. Blood 2012;120:4840–4845.
  • Van der Helm LH, Veeger NJGM, Van Marwijk Kooy M, et al. Azacitidine results in comparable outcome in newly diagnosed AML patients with more or less than 30% bone marrow blasts. Leuk Res 2013;37:877–882.
  • Tawfik B, Sliesoraitis S, Lyerly S, et al. Efficacy of the hypomethylating agents as frontline, salvage or consolidation therapy in adults with acute myeloid leukemia. Ann Hematol 2013;93:47–55.
  • Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006;108:419–425.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.